Portal de recerca
ENSAYO CLINICO FASE IIA, MULTICÉNTRICO, DOBLE CIEGO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE DOSIS BAJAS DE DIAZOXIDA ORAL EN EL TRATAMIENTO DE LA ESCLEROSIS MÚLTIPLE.
Dades bàsiques
- Protocol:
- NT-KO-003-2010-01
- EURDRACT:
- 2010-023048-34
- NCT:
- Centre:
- Any inici:
- Any de finalització:
Documents
- No hi ha documents
Participants
Grups d'Investigació
Finançadors - Promotors
Resultats de l'Assaig Clínic
An algorithm to predict intrathecal synthesis of IgG with high efficiency
Tortosa-Carreres, Jordi; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Analysis of "task-positive" and "task-negative" functional networks during the performance of the Symbol Digit Modalities Test in patients at presentation with clinically isolated syndrome suggestive of multiple sclerosis.
Forn C; (...); Filippi M
Article. 10.1007/s00221-012-3380-5. 2013
Anti-CD20 monoclonal antibodies in primary progressive multiple sclerosis: a real-life comparative study of rituximab vs. ocrelizumab
Alcala, C.; (...); Casanova, B.
Meeting Abstract. 2021
Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer's Disease and Frontotemporal Dementia.
Álvarez-Sánchez L; (...); Cháfer-Pericás C
Article. 10.3390/ijms24021226. 2023
Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.
Lunemann JD; (...); Comabella M
Article. 10.1212/NXI.0000000000200270. 2024
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.
Monreal, Enric; (...); Villar LM
Article. 10.1001/jamaneurol.2023.0010. 2023
Autologous hematopoietic stem cell transplantation in multiple sclerosis: updating outcomes in the Valencian cohort.
Boix Lago, A.; (...); Casanova Estruch, B.
Meeting Abstract. 2023
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis
Casanova, B; (...); Coret, F
Article. 10.1007/s10072-017-2933-6. 2017
Basal levels of serum neurofilament light in normal aging and multiple sclerosis patients
Gasque Rubio, R.; (...); Casanova Estruch, B.
Meeting Abstract. 2021
Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series.
Quintanilla-Bordás C; (...); Casanova B
Article. 10.3389/fneur.2022.897275. 2022
Cerebrospinal fluid kappa free light chains and IgM index for diagnosis and prognosis in multiple sclerosis
Gil-Perotin, S.; (...); Casanova, B.
Meeting Abstract. 2021
Cervical spinal cord T2 lesions independently predict early conversion to secondary progressive multiple sclerosis: a longitudinal 10-year study
Lacruz-Ballester, L.; (...); Casanova-Estruch, B.
Meeting Abstract. 2021
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study
Oreja-Guevara, Celia; (...); Rio, Jordi
Article. 10.1016/j.msard.2024.105787. 2024
Clinical experience with rituximab in the treatment of refractory multiple sclerosis
Gascon, F.; (...); Coret, F.
Meeting Abstract. 2014
Clinical experiences with cannabinoids in spasticity management in multiple sclerosis
Lorente Fernández L; (...); Casanova-Estruch B
Article. 10.1016/j.nrl.2013.06.014. 2014
Clinical trajectories of patients with multiple sclerosis from onset and their relationship with serum neurofilament light chain levels
Quintanilla-Bordas, Carlos; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2024.1477335. 2024
Cognitive performance and health-related quality of life in patients with neuromyelitis optica spectrum disorder
Lopez-Soley, Elisabet; (...); Solana, Elisabeth
Meeting Abstract. 2022
Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder.
Lopez-Soley E; (...); Solana E
Article. 10.3390/jpm12050743. 2022
Comparative Assessment of Simoa and Lumipulse for Measuring Serum Neurofilament Light Chain in Multiple Sclerosis Patients
Gasque-Rubio, Raquel; (...); Perez-Miralles, Francisco
Article. 10.1155/2024/1950913. 2024
Consensus on early detection of disease progression in patients with multiple sclerosis
Meca-Lallana, Jose E.; (...); Oreja-Guevara, Celia
Article. 10.3389/fneur.2022.931014. 2022
Cytokines profile in the cerebrospinal fluid in chronic relapsing inflammatory demyelinating diseases of the central nervous system
Simo-Castello, M.; (...); Coret, F.
Meeting Abstract. 2014
Characterization of the gait in patients with relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis measured by FeetMe (R) integrated sensor insole system: Results of the interim analysis
Izquierdo Ayuso, G.; (...); Casanova Estruch, B.
Meeting Abstract. 2021
Deciphering Multiple Sclerosis Progression.
Meca-Lallana, Virginia; (...); Perez-Miralles, Francisco Carlos
Review. 10.3389/fneur.2021.608491. 2021
Design and Validation of an Expanded Disability Status Scale Model in Multiple Sclerosis.
Barreiro-Gonzalez, Antonio; (...); Casanova, Bonaventura
Article. 10.1159/000519772. 2022
Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients
Casanova, B; (...); Coret, F
Article. 10.1007/s10072-018-3442-y. 2018
Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.
Brieva, Luis; (...); Moral, Ester
Article. 10.1016/j.msard.2022.103805. 2022
Does benign multiple sclerosis exist?
Verdini Martinez, Laura; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Dynamic 18F-FDG PET to detect differences among patients with progressive and relapsing multiple sclerosis: a pilot study
Quintanilla Bordas, Carlos; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers
Alvarez-Sanchez, Lourdes; (...); Chafer-Pericas, Consuelo
Article. 10.3390/ijms241814151. 2023
Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study.
Meca-Lallana, J E; (...); Calles Hernandez, C
Article. 10.1016/j.nrleng.2021.06.006. 2023
Early beginning of alemtuzumab: changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study
Meca-Lallana, J. E.; (...); Hernandez, C. Calles
Article. 10.1016/j.nrl.2021.06.007. 2024
Economic impact and clinical profile of the secondary progressive multiple sclerosis (SPMS) patient: the DISCOVER study
Oreja-Guevara, C.; (...); Meca-Lallana, J. E.
Meeting Abstract. 2021
Eculizumab for a catastrophic relapse in NMOSD: case report.
Gorriz, David; (...); Casanova, Bonaventura
Article. 10.1007/s10072-023-06971-x. 2023
Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
Meca-Lallana JE; (...); Llarena C
Article. 10.1007/s40120-023-00557-7. 2023
Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
Alcala, Carmen; (...); Casanova, Bonaventura
Article. 10.1007/s00415-022-10989-0. 2022
Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study
Alcala, C; (...); Casanova, B
Article. 10.1007/s00415-018-8899-3. 2018
Elevation of serum neurofilament light-chain levels disclose possible occult progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient receiving ozanimod: a case report.
Quintanilla-Bordás C; (...); Pérez-Miralles FC
Case Reports. 10.3389/fimmu.2024.1465678. 2024
Escalation vs. Early Intense Therapy in Multiple Sclerosis.
Casanova, Bonaventura, Quintanilla-Bordas, Carlos, Gascon, Francisco
Article. 10.3390/jpm12010119. 2022
Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?
Tortosa-Carreres J; (...); Pérez-Miralles FC
Article. 10.1016/j.jneuroim.2024.578428. 2024
Fingolimod plus steroids prevents return to clinical activity after natalizumab withdrawal
Alcala, C.; (...); Casanova, B.
Article. 2013
High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis.
Castillo-Villalba, Jessica; (...); Casanova, Bonaventura
Article. 10.3389/fimmu.2022.827738. 2022
Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study
Meca-Lallana, Jose E.; (...); Maurino, Jorge
Article. 10.1007/s40120-022-00356-6. 2022
Impact of neuromyelitis optica spectrum disorder on quality of life: Assessing the patients' perspective
Meca-Lallana, Jose; (...); Maurino, Jorge
Meeting Abstract. 10.1016/j.jns.2021.118844. 2021
Improvements in Quality of Life of Patients with Multiple Sclerosis receiving Alemtuzumab in Clinical Practice: LEMVIDA study
Meca Lallana, Jose; (...); Forner, Mireia
Meeting Abstract. 10.1212/WNL.0000000000202381. 2023
Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study.
Meca-Lallana, Jose Eustasio; (...); Toledo, Baldo
Article. 10.1186/s41687-024-00822-9. 2024
Improving the efficiency of free kappa light chains as diagnostic biomarker of Multiple Sclerosis by using a novel algorithm.
Tortosa-Carreres J; (...); Pérez-Miralles FC
Article. 10.1016/j.msard.2023.104997. 2023
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis
Comabella, Manuel; (...); Luenemann, Jan D.
Article. 10.1007/s00415-024-12763-w. 2025
Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation
Beltrán E; (...); Dornmair K
Article. 10.1093/brain/awu205. 2014
Is it cost-effective to request IgM oligoclonal bands against lipids in daily practice as a biomarker for poor prognosis in multiple sclerosis?
Ribes Garcia, Sara; (...); Bonaventura, Casanova Estruch
Article. 10.1016/j.msard.2023.105033. 2023
Lipid-specific IgM oligoclonal bands in clinically isolated syndrome: 5-years follow-up
Molla, B.; (...); Casanova, B.
Meeting Abstract. 2014
Lipid-specific oligoclonal IgM bands: is there any influence on the response to treatment with fingolimod?
Perez-Romero, L.; (...); Casanova, B.
Meeting Abstract. 2014
Long-term efficacy of alemtuzumab in multiple sclerosis: a real word multicenter Spanish experience
Rubio Alcantud, Almudena; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Long-term treatment effect over disability progression in patients with relapsing multiple sclerosis
Estruch, BC; (...); Coret, F
Meeting Abstract. 2017
Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview
Garcia-Foncillas, J; (...); Gomez, MVP
Review. 10.1007/s40291-021-00544-4. 2021
miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.
Munoz-San Martin, Maria; (...); Ramio-Torrenta, Lluis
Article. 10.1212/NXI.0000000000200069. 2023
Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma.
Pedrero Prieto, Manuel; (...); Casanova Estruch, Bonaventura
Article. 10.1007/s10072-023-07252-3. 2023
NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.
Alcala, C.; (...); Casanova, B.
Article. 10.1007/s00415-021-10926-7. 2022
Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis.
Alcala Vicente, Carmen; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2022.991596. 2022
Oligoclonal M bands distinguish two MS populations based on neurofilament light chain levels in patients without inflammatory activity
Castillo, J.; (...); Casanova, B.
Meeting Abstract. 2022
Oligoclonal M bands unveil occult inflammation in multiple sclerosis.
Casanova B; (...); Pérez-Miralles F
Article. 10.1016/j.msard.2022.104118. 2022
Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies.
Coret F; (...); Casanova B
Article. 10.1177/2055217318783347. 2018
Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder
Meca-Lallana, JE; (...); Maurino, J
Article. 10.2147/PPA.S305707. 2021
Perception of stigma in people with neuromyelitis optica spectrum disorders (PERSPECTIVES-NMO Study)
Lallana, Jose Meca; (...); Maurino, Jorge
Meeting Abstract. 2021
Pharmacotherapeutic management of advanced therapy medicinal products
Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia
Article. 10.7399/fh.13036. 2022
Potential Biomarkers Associated with Multiple Sclerosis Pathology.
Mathur, Deepali; (...); Casanova, Bonaventura
Article. 10.3390/ijms221910323. 2021
Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.
Tortosa-Carreres J; (...); Pérez-Miralles FC
Article. 10.1016/j.msard.2024.105734. 2024
Quantifying the patient ' s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire
Meca-Lallana, JE; (...); Ballesteros, J
Article. 10.1371/journal.pone.0255317. 2021
Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.
Ramo-Tello, Cristina; (...); Rovira À
Article. 10.3390/jpm12010006. 2021
Relapsing inflammatory optic neuropathy: clinical description in a serie of 16 patients
Navarro, L.; (...); Casanova, B.
Meeting Abstract. 2014
Renal function influences serum neurofilament light chain levels in patients with multiple sclerosis
Gasque Rubio, R.; (...); Casanova Estruch, B.
Meeting Abstract. 2022
Renal function's impact on serum neurofilament levels in patients with multiple sclerosis: an exploratory analysis.
Tortosa-Carreres, Jordi; (...); Perez-Miralles, Francisco
Article. 10.1007/s10072-024-07772-6. 2024
SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.
Arrambide, Georgina; (...); Meca-Lallana, Jose E
Article. 10.1212/NXI.0000000000001024. 2021
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
Fissolo, Nicolas; (...); Comabella, Manuel
Article. 10.1136/jnnp-2023-332251. 2023
Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.
Monreal E; (...); Villar LM
Article. 10.1093/brain/awae260. 2024
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels at Disease Onset for Prediction of the Risk of Disability Worsening in Patients with Multiple Sclerosis
Monreal, Enric; (...); Villar Guimerans, Luisa Maria
Meeting Abstract. 2023
Serum neurofilament light chain and glial fibrillary acidic protein levels at disease onset unveil immunological pathways of disability acquisition in multiple sclerosis
Monreal, Enric; (...); Villar Guimerans, Luisa Maria
Meeting Abstract. 2024
Serum Neurofilament Light Chain is a surrogate marker of NEDA-3 in Multiple Sclerosis
Gascon Gimenez, Francisco Guillermo; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Symptom severity in Neuromyelitis Optica Spectrum Disorder from the patients' perspective
Meca-Lallana, J.; (...); Maurino, J.
Meeting Abstract. 2021
Treatment of multiple sclerosis with Rituximab: a multicenter Spanish experience
Alcala, C.; (...); Casanova, B.
Meeting Abstract. 2021
Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience.
Gascon-Gimenez, Francisco; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2023.1060696. 2023
Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain.
Landete, Lamberto; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2021.727586. 2021
Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice
Alcala-Vicente, C; (...); Casanova-Estruch, B
Article. 10.33588/rn.6410.2016359. 2017